Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Genome-wide Association Study of Susceptibility to Respiratory Syncytial Virus Hospitalization in Young Children <5 Years of age.

Egeskov-Cavling AM. et al, (2024), The Journal of infectious diseases, 230, e333 - e341

Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination

Richardson E. et al, (2024), Frontiers in Immunology, 15

Improved estimates of COVID-19 correlates of protection, antibody decay and vaccine efficacy waning: a joint modelling approach

Phillips DJ. et al, (2024)

Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.

Feng S. et al, (2024), Health technology assessment (Winchester, England), 28, 1 - 109

Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial.

Williams LR. et al, (2024), Vaccine

Pathogen diversity and antimicrobial resistance transmission of Salmonella enterica serovars Typhi and Paratyphi A in Bangladesh, Nepal, and Malawi: a genomic epidemiological study.

Dyson ZA. et al, (2024), The Lancet. Microbe

Towards paratyphoid control: the vital role of the challenge model

McCann N. et al, (2024), The Lancet, 403, 2780 - 2781

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

Costa Clemens SA. et al, (2024), The Lancet. Microbe

Inflammation of the Nasal Mucosa is Associated with Susceptibility to Experimental Pneumococcal Challenge in Older Adults

Urban BC. et al, (2024), Mucosal Immunology

Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine

Cotugno N. et al, (2024), JCI Insight, 9

A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial

Dinh Thiem V. et al, (2024), Vaccine

Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: A pre-post comparison study.

Kandasamy R. et al, (2024), Vaccine

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study

Jackson S. et al, (2024), The Lancet Microbe

The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.

Maytum A. et al, (2024), The Pediatric infectious disease journal

Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease

Drury RE. et al, (2024), Nature Communications, 15

A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.

Iwata S. et al, (2024), Scientific reports, 14

Evaluating the Impact of the BioFire FilmArray in Childhood Meningitis: An Observational Cohort Study.

Kadambari S. et al, (2024), The Pediatric infectious disease journal, 43, 345 - 349

Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.

GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators None., (2024), The Lancet. Infectious diseases

Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT

Iro MA. et al, (2024), Efficacy and Mechanism Evaluation, 1 - 53

Typhoid conjugate vaccines: a step towards typhoid control

Shakya M. and Pollard AJ., (2024), The Lancet Global Health, 12, e535 - e536

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?